Aceragen
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 26
- Market Cap
- -
- Website
- http://www.aceragen.com
- Introduction
Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations
- Conditions
- Cystic FibrosisCystic Fibrosis Pulmonary Exacerbation
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Aceragen
- Registration Number
- NCT05641298
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸Central Florida Pulmonary Group, Orlando, Florida, United States
🇺🇸Nemours Children's Health - Pensacola, Pensacola, Florida, United States